2 weeks Ago By Defense World Staff
Rhumbline Advisers raised its stake in Acrivon Therapeutics, Inc. ( NASDAQ:ACRV – Free Report ) by 48.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.
The firm owned 16,209 shares of the company’s stock after buying an additional 5,320 shares during the quarter. Rhumbline Advisers owned 0.05% of Acrivon Therapeutics worth $94,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its stake in Acrivon Therapeutics by 50.1% in the second quarter.
Bank of New York Mellon Corp now owns 36,632 shares of the company’s stock valued at $212,000 after acquiring an additional 12,219 shares during the period. Baker BROS. Advisors LP acquired a new stake in shares of Acrivon Therapeutics in the 1st quarter valued at about $378,000.
American International Group Inc. boosted its position in Acrivon Therapeutics by 39.2% during the 1st quarter.
American International Group Inc. now owns 6,016 shares of the company’s stock worth $43,000 after acquiring an additional 1,695 shares during the last quarter. Finally, Vanguard Group Inc.
lifted its position in Acrivon Therapeutics by 6.6% during the 1st quarter. Vanguard Group Inc.
now owns 507,185 shares of the company’s stock worth $3,626,000 after buying an additional 31,208 shares in the last quarter. Institutional investors own 71.62% of the company’s stock.
Analyst Ratings Changes A number of brokerages have recently issued reports on ACRV. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of Acrivon Therapeutics in a research note on Monday, September 16th.
LADENBURG THALM/SH SH upgraded shares of Acrivon Therapeutics from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Monday, September 16th. JMP Securities reiterated a “market outperform” rating and issued a $17.
00 price target on shares of Acrivon Therapeutics in a research note on Monday, September 16th. BMO Capital Markets restated an “outperform” rating and set a $28.00 price objective (up from $25.
00) on shares of Acrivon Therapeutics in a research note on Monday, September 16th. Finally, Piper Sandler Companies reiterated a “buy” rating and issued a $30.00 target price on shares of Acrivon Therapeutics in a research note on Friday, September 6th.
Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Acrivon Therapeutics currently has an average rating of “Buy” and a consensus price target of $23.86. Acrivon Therapeutics Price Performance Shares of ACRV opened at $7.
00 on Tuesday. The company’s 50-day moving average is $8.13 and its 200-day moving average is $7.
83. The firm has a market capitalization of $216.14 million, a PE ratio of -2.
43 and a beta of 0.81. Acrivon Therapeutics, Inc.
has a fifty-two week low of $3.19 and a fifty-two week high of $11.90.
Acrivon Therapeutics ( NASDAQ:ACRV – Get Free Report ) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.
60) by $0.08. Analysts predict that Acrivon Therapeutics, Inc.
will post -2.4 earnings per share for the current fiscal year. Acrivon Therapeutics Company Profile ( Free Report ) Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform.
The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. See Also Five stocks we like better than Acrivon Therapeutics Learn Technical Analysis Skills to Master the Stock Market TJX Stock: A Buying Opportunity Before the Holiday Rush How Investors Can Find the Best Cheap Dividend Stocks Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge What Are Dividends? Buy the Best Dividend Stocks Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth Want to see what other hedge funds are holding ACRV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acrivon Therapeutics, Inc.
( NASDAQ:ACRV – Free Report ). Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
